The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.
 
Jessica Cecile Hassel
Honoraria - Almirall Hermal GmbH; Bristol Myers Squibb Foundation; MSD; Novartis; Roche Pharma AG; Sanofi; Sun Pharma
Consulting or Advisory Role - Sanofi Aventis GmbH; Sun Pharma
Research Funding - 4SC (Inst); BioNTech AG (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Idera (Inst); Immunocore (Inst); Novartis (Inst); Philogen (Inst)
 
Carola Berking
Honoraria - Bristol-Myers Squibb; Immunocore; LEO Pharma; MSD; Novartis; Roche Pharma AG; Sanofi/Aventis
Consulting or Advisory Role - Almirall Hermal GmbH; Bristol-Myers Squibb; Immunocore; MSD; Novartis; Roche; Sanofi/Aventis; Sanofi/Regeneron
 
Max Schlaak
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Kyowa Kirin; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Novartis; Pierre Fabre; Sun Pharma
 
Thomas Eigentler
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Philogen; Roche
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; Bayer; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - 4SC; Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma
Research Funding - Amgen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pierre Fabre; Roche; Sun Pharma
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; Lunaphore Technologies; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seattle Genetics; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Bastian Schilling
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pfizer/EMD Serono; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi Aventis GmbH
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
 
Svetlana Hamm
Employment - 4SC
 
Frank Hermann
Employment - 4SC
Leadership - 4SC
Patents, Royalties, Other Intellectual Property - I am partly holder of patent rights within 4SC AG.
 
Philip Gero Reimann
Employment - 4SC
Stock and Other Ownership Interests - 4SC; Adaptimmune; BioNTech AG; Bluebird Bio; Bristol-Myers Squibb; crispr therapeutics; Editas Medicine; Evotec; Medigene; Sartorius
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron